Posted by Michael Wonder on 24 May 2022
Neuronascent receives FDA rare paediatric drug designation for NNI-351 treatment for Fragile X syndrome
24 May 2022 - Neuronascent today announced that the US FDA granted rare paediatric designation for NNI-351 for Fragile X syndrome.
Evaluation of NNI-351 in preclinical models of FXS (supported in part by the FRAXA organisation), by selectively prompting neural progenitor cells to become neurons, i.e., neurogenesis, NNI-351 reverses behavioural deficits back to normal levels.
